pipeline
FDA knocks back Takeda’s blockbuster hope TAK-721
Phil Taylor
eosinophilic oesophagitis, Immunology and inflammation, pipeline, Takeda
0 Comment
GSK sees £20bn peak sales potential in late-stage pipeline
Phil Taylor
Blenrep, consumer health, Emma Walmsley, GlaxoSmithKline, M&A, mRNA, pipeline, respiratory syncytial virus, vaccine
0 Comment
Genmab axes development of AXL-targeting cancer drug enapotamab vedotin
Richard Staines
BerGenBio, cancer, Genmab, pipeline, R&D
0 Comment
News/ News/ R&D/ Top stories
Novartis set to overcome $14 billion patent cliff say analysts
Richard Staines
biosimilars, cancer, inflammatory diseases, Novartis, pipeline, R&D, Sandoz
0 Comment
News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing
AstraZeneca ‘probably couldn’t run Gilead any better:’ analyst
Phil Taylor
AstraZeneca, Gilead Sciences, M&A, Oncology, pipeline
0 Comment
AZ reportedly mulls biggest-ever pharma merger with Gilead
Richard Staines
AstraZeneca, COVID-19, Gilead, infectious diseases, M&A, Oncology, pipeline
0 Comment
NodThera raises $55m in Series B round to trial inflammatory disease drugs
Richard Staines
Biotech, Funding, inflammatory diseases, NodThera, pipeline, R&D
0 Comment
News/ News/ R&D/ Top stories
Failed trial puts future of UCB’s epilepsy drug padsevonil in doubt
Phil Taylor
central nervous system, epilepsy, pipeline, UCB
0 Comment